Bill · S. 1095· Senate(119-S-1095)
Stop STALLING Act
- Introduced
- 3/24/2025
- Last activity
- 4/10/2025 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
- Sponsored by
- Amy Klobuchar
- Cosponsors
- - 4 - 2
- Introduced
- On Calendar
What this bill would do
The "Stop STALLING Act" aims to empower the Federal Trade Commission to prevent the use of sham citizen petitions that interfere with the approval of competing generic drugs or biosimilars. It seeks to promote competition and allow for the efficient review of good-faith petitions regarding public health. The bill defines a "sham" as an objectively baseless petition used to interfere with a competitor's business. Under this Act, submitting such petitions would be considered an unfair method of competition. The Federal Trade Commission would have the authority to commence civil actions to recover penalties against violators.
Yes· 3 of 6
Does this lower the price of prescription medicines?+7
By deterring sham petitions that delay generics, the bill helps lower prescription drug costs through increased competition.
Would households on low incomes be better off under this?+5
Lower drug costs through increased competition benefit low-income households.
Would middle-income households be better off under this?+5
Lower drug costs through increased competition benefit middle-class households.
The opposite
Would business owners be better off under this?-5
Generic drug manufacturers may benefit from increased competition, while brand-name drug makers may face increased penalties and competition.
Who it would affect, and how
Potential Positive Impacts for People
-
Fostering Competition and Efficiency: The bill aims to foster competition and facilitate the efficient review of petitions that are filed in good faith to raise legitimate public health concerns (Section 2).
-
Deterrence of Sham Petitions: By enabling the Federal Trade Commission to deter the filing of sham citizen petitions, the bill seeks to prevent interference with the approval of competing generic drugs or biosimilars (Section 2).
Potential Negative Impacts for People
-
Civil Penalties for Violators: Any person found liable for submitting a sham covered petition or series of covered petitions could face significant civil penalties. These penalties may be up to the greater of any revenue earned from the sale of the drug product referenced in the petition during the review period or $50,000 for each calendar day the petition was under review (Section 2(c)(4)).
-
Presumption of Sham Status: A covered petition may be presumed to be part of a sham series if the Secretary of Health and Human Services determines it was submitted primarily to delay the approval of a covered application and refers that determination to the Commission in writing (Section 2(c)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households+5Good For Middle Class Households+5Good For Retirees+5Good For Business Owners-5
- Healthcare
- Reduces Prescription Drug Costs+7
- Economy And Finance
- Improves Consumer Protection+5
- Governance And Ideology
- Increases Federal Power+5
- 4/10/2025
- Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
- 4/3/2025
- Committee on the Judiciary. Ordered to be reported without amendment favorably.
- 3/24/2025
- Read twice and referred to the Committee on the Judiciary.
- 6 Cosponsors added.
- Introduced in Senate
Richard BlumenthalDemocrat · Connecticut
Cory BookerDemocrat · New Jersey
Ted CruzRepublican · Texas
Richard DurbinDemocrat · Illinois
Chuck GrassleyRepublican · Iowa
Peter WelchDemocrat · Vermont